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Background: Prorenin and renin are both involved in atherosclerosis. However, the role of plasma prorenin and
renin in the development and progression of coronary artery disease (CAD) is still not clear. Thus, we aimed to
examine the relationships among plasma prorenin concentration, CAD and clinical parameters.
Methods: We measured plasma prorenin and renin concentrations and other parameters in 85 patients who
underwent coronary angiography. Patients were divided into a CAD group (≥75 % stenosis in one or more
coronary arteries) and a non-CAD group.
Results: There was a weak correlation between prorenin and plasma renin concentration (r =0.35, p =0.001), and
plasma renin activity (r =0.34, p =0.001). There was no significant difference in the plasma prorenin concentration
between the CAD group and non-CAD group. However, patients with a high plasma prorenin concentration
frequently suffered CAD. Receiver-operating-characteristic curve analysis showed that the optimal cutoff value
of plasma prorenin concentration to detect CAD was 1,100 pg/ml, with a positive predictive value of 94 % and
a negative predictive value of 36 %.
Conclusion: The plasma prorenin concentration increases with increases in plasma renin concentration. Higher
plasma prorenin concentration (>1,100 pg/ml) plays a role in the development of CAD.
Keywords: Prorenin, Renin, Coronary artery diseaseIntroduction
The renin-angiotensin system is a key regulator of the
cardiovascular system. The principal effector hormone
of the classic renin-angiotensin system is angiotensin II.
The conversion of angiotensinogen to angiotensin I by
renin is the rate limiting step in the synthesis of renin-
angiotensin II. Chronic activation of renin-angiotensin
system is a major contributing factor to the pathogenesis
and progression of cardiovascular disease. In fact, higher
plasma renin activity (PRA) was reported to be associ-
ated with an increased risk of myocardial infarction in
the patients with hypertension [1]. Furthermore, another
recent study demonstrated that high PRA was associated* Correspondence: masanori@ya2.so-net.ne.jp
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tients with coronary artery disease (CAD) [2].
For many years, prorenin was considered to be an in-
active precursor of renin. However, since the discovery
of (pro)renin receptors, prorenin is now regarded as an
important regulator of the renin-angiotensin system. Both
prorenin and renin bind to (pro)renin receptors, and
stimulation of (pro)renin receptors has been reported to
be involved in the development of diabetic nephropathy
[3] cardiac injury [4] and vascular damage [5]. Prorenin is
released constitutively from the kidney, and its blood
plasma levels are approximately 10-fold higher than those
of renin. Chronic stimulation of the renin-angiotensin sys-
tem usually increases renal prorenin-renin conversion,
thereby decreasing the relative amount of prorenin in the
circulation [6]. Furthermore, plasma prorenin concentra-
tion is markedly increased in diabetes mellitus patientsarticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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concentration and its pathophysiological role in patients
with CAD are not clear. Therefore, in the present study,
we aimed to examine the relationships among plasma pro-
renin concentration, CAD and clinical parameters.
Methods
Study patients
We initially enrolled 100 consecutive patients with chest
pain and/or chest discomfort who underwent elective
coronary angiography for suspicion of CAD. We excluded
subjects with unstable angina or myocardial infarction
within the previous three months and severe heart failure
(NYHA class IV and/or a left ventricular ejection frac-
tion ≤ 30 %). The final study population consisted of 85
patients who underwent coronary angiography. Patients
were diagnosed with CAD when one or more of their
coronary arteries had a stenosis ≥75 %. According to
the angiographical diagnosis, patients were divided into
two groups (CAD group or non-CAD group). Risk factors
for CAD were evaluated in enrolled patients, including
hypertension (HTN) (medication-dependent or systolic
BP ≥140 and/or diastolic BP ≥90 mmHg), type 2 diabetes
mellitus (DM) (medication-dependent or hemoglobin (Hb)
A1c ≥ 6.5 %) and dyslipidemia (medication-dependent, LDL
cholesterol ≥140 mg/dl and/or HDL cholesterol <40 mg/
dl). The protocol was approved by the ethics committee of
Gifu University Graduate School of Medicine. All of the pa-
tients gave informed consent before the start of study. The
investigation conformed with the principles outlined in the
Declaration of Helsinki (Br Med J 1964; ii:177).
Hemodynamic parameters
Blood pressure and pulse rate were measured. Left
ventricular ejection fraction (LVEF) left ventricular
end-diastolic dimension (LVEDd) and left ventricular
end-systolic dimension (LVESd) were obtained by echo-
cardiography. Echocardiographic measurements were used
to calculate LVEF based on a disk summation method
using the apical 2- and 4-chamber views.
Measurements of plasma prorenin and renin
concentration
Blood samples were obtained from the antecubital vein
in the morning while the patients were in a fasting state
on the day of cardiac catheterization. The samples were
collected into sterile tubes, immediately placed on ice,
centrifuged at 3,000 x g for 10 min at 4 °C, and rapidly
frozen and stored at −80 °C until analysis. Plasma prorenin
concentrations were measured using an ELISA kit (LINCO
Research Inc., St. Charles, MO, USA). Plasma renin
concentrations were also measured using an ELISA kit
(LINCO Research Inc., St. Charles, MO, USA). Plasma
brain natriuretic peptide (BNP) levels were measuredby immunoradiometric assay (Shionoria BNP RIA kit;
Shionogi, Osaka, Japan). We also measured hemoglobin
A1c (HbA1c), total cholesterol, LDL-cholesterol, HDL-
cholesterol and estimated glomerular filtration rate (eGFR).Statistical analysis
The data are shown as the mean ± one standard deviation.
Categorical data were summarized as percentages and
compared with a chi-square test or Fisher’s exact test.
The normality of data distributions was tested using
the Kolmogorov-Smirnov test. The significance of the
differences between groups for variables that were normally
distributed and had similar variances was determined by an
unpaired Student’s t test. Otherwise, a Mann–Whitney U
test was used to compare the differences between groups.
Linear regression analysis was performed to examine the
correlations between plasma prorenin concentration and
other parameters. A p value <0.05 was considered signifi-
cant. All statistical analyses were performed using Stat View
version 5.0 (SAS Institution Inc, Cary, NC, USA).Results
Patient’s characteristics
Patient characteristics are shown in Table 1. The patients
were taking oral angiotensin-converting enzyme inhibitors
(ACEIs) or angiotensin II receptor blockers (ARBs) (n =24),
calcium channel blockers (n =30), beta-blockers (n =12), or
diuretics (n =9). There were no significant differences be-
tween the two groups in history of hypertension, current
smoking or concomitant medication use. However, history
of DM, history of dyslipidemia and age were significantly
greater in the CAD group than in the non-CAD group.Hemodynamic parameters
As shown in Table 2, there were no significant differences
in heart rate, systolic blood pressure, diastolic blood pres-
sure or LVEDd between the CAD group and the non-CAD
group. The LVEF was significantly greater in the non-CAD
group than in the CAD group.Plasma prorenin concentration and plasma renin
concentration
There was a weak correlation between the plasma prorenin
concentration and plasma renin concentration (r =0.35,
p =0.001), and plasma renin activity (r =0.34, p =0.001)
(Fig. 1). However, there was no correlation between the
plasma prorenin concentration and aldosterone (p =0.15),
BNP (p =0.17) or eGFR (p =0.16) (Fig. 1). The LVEF
was not correlated with the plasma prorenin concentration
(p =0.83).







(n = 26) (n = 59)
Clinical characteristics
Men (%) 20 (76.9) 39 (66.1) 0.27
Age, years 62 ± 15 69 ± 9 0.007
Body mass index 22.7 ± 3.1 23.8 ± 3.0 0.12
Hypertension, n (%) 12 (46.1) 36 (61.0) 0.15
Diabetes mellitus, n (%) 5 (19.2) 28 (47.5) 0.010
Dyslipidemia, n (%) 5 (19.2) 32 (56.1) 0.002
Systolic blood pressure (mmHg) 125 ± 18 130 ± 18 0.21




70 ± 6 62 ± 11 0.001
LVEDd (mm) 45 ± 7 47 ± 5 0.15
LVSWth (mm) 9.2 ± 1.7 9.5 ± 1.3 0.41
LVPWth (mm) 9.6 ± 1.5 9.7 ± 1.5 0.72
Medications
ARBs or ACEIs, n (%) 8 (30.8) 16 (27.1) 0.81
Beta-blockers, n (%) 3 (11.5) 9 (15.2) 0.61
Calcium channel blockers, n (%) 7 (26.9) 23 (39.0) 0.23
Diuretics, n (%) 2 (7.7) 7 (11.9) 0.71
LVEDd: Left ventricular end-diastolic dimension, LVSWth: left ventricular septal
wall thickness, LVPWth: left ventricular posterior wall thickness, ACEIs:
angiotensin-converting enzyme inhibitors, ARBs: Angiotensin II receptor blockers
Table 2 Patient laboratory characteristics
Non-CAD group CAD group p-value
(n = 26) (n = 59)
Prorenin (pg/ml) 490 (321–786) 522 (297–1097) 0.70
Plasma renin concentration
(pg/ml)
5.8 (3.3 - 9.8) 6.3 (4.4 - 12.0) 0.84
Plasma renin activity
(ng/ml/hr)
1.0 (0.5 - 2.1) 1.1 (0.6 - 2.4) 0.83
Aldosterone (pg/ml) 85 (65–130) 74 (59–98) 0.40
Brain natriuretic peptide
(ng/ml)
20 (14–55) 32 (14–62) 0.38
Cystatin C (mg/dl) 1.09 ± 0.87 1.09 ± 0.38 0.97
Creatinine (mg/ml) 1.01 ± 1.48 0.85 ± 0.27 0.42
Estimated GFR
(ml/min/1.73 m2)
77.1 ± 28.3 69.6 ± 19.2 0.16
Blood urea nitrogen (mg/dl) 18.0 ± 20.1 15.9 ± 4.1 0.45
Hemoglobin A1c (%) 5.7 ± 0.7 6.1 ± 1.1 0.16
Total cholesterol (mg/dl) 191 ± 43 187 ± 33 0.75
LDL cholesterol (mg/dl) 115 ± 39 112 ± 31 0.71
HDL cholesterol (mg/dl) 51 ± 13 48 ± 14 0.39
Triglycerides (mg/dl) 114 ± 56 139 ± 72 0.11
C-reactive protein (mg/dl) 0.24 ± 0.52 0.18 ± 0.21 0.52
Total protein (g/dl) 6.68 ± 0.52 6.72 ± 0.43 0.68
Albumin (g/dl) 3.99 ± 0.32 4.13 ± 0.30 0.054
Sodium (mEq/l) 141.1 ± 2.1 140.3 ± 2.3 0.57
Potassium (mEq/l) 4.10 ± 0.41 4.05 ± 0.35 0.53
Cl (mEq/l) 105.3 ± 3.2 105.4 ± 2.7 0.92
Numerical data are expressed as the mean ± one standard deviation.
Non-parametric data are expressed as the median (interquartile range).
GFR: glomerular filtration rate
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There was also no significant difference in the plasma
renin activity or plasma prorenin concentration between
the CAD group and non-CAD group (Fig. 2). There was
also no significant difference in the plasma prorenin
concentration between patients with and without DM
(635 ± 541 and 824 ± 533 pg/ml, respectively). There were
also no significant differences in the plasma prorenin
concentration in the patients with one-vessel disease,
two-vessel disease and three-vessel disease (780 ± 681,
651 ± 507 and 884 ± 580 pg/ml, respectively). However,
patients with a high plasma prorenin concentration
frequently suffered from CAD (Fig. 2). Receiver-operating-
characteristics curve analysis showed that the optimal cut-
off value of the plasma prorenin concentration to detect
CAD was 1,100 pg/ml with a positive predictive value for
estimating CAD of 94 % and a negative predictive value of
36 % (Table 3) (Fig. 3). Only one of 26 patients with ele-
vated plasma prorenin concentration (>1,100 pg/ml) did
not have CAD (Fig. 2). The optimal cutoff value of the
plasma renin activity to detect CAD was 0.8 ng/ml/hr with
a positive predictive value of 72 %, and a negative predict-
ive value of 32 %. A higher plasma prorenin concentrationwas more accurate than a higher PRA for the detection of
CAD. Laboratory and clinical characteristics in the CAD
group with patients stratified based on prorenin levels are
shown in Table 4.
Discussion
The key findings in the present study were as follows: (1)
the optimal cutoff value of plasma prorenin concentration
to detect CAD was 1,100 pg/ml with a positive predictive
value of 94 % and a negative predictive value of 36 %; (2)
patients with high plasma prorenin concentration
(>1,100 pg/ml) frequently suffered CAD; (3) the plasma
prorenin concentration was positively correlated with the
plasma renin concentration; (4) the plasma prorenin con-
centration was not correlated with LVEF, HbA1c, BNP or
eGFR.
Plasma prorenin concentration and coronary artery disease
Prorenin is an inactive precursor of renin. Both prorenin
and renin bind to (pro)renin receptors, and stimulation
of these receptors activates intracellular cascades such as
Fig. 1 Relationship between plasma prorenin concentration and laboratory parameters. PRC: plasma renin concentration, PRA: plasma renin
activity, HbA1c: hemoglobin A1c, BNP: brain natriuretic peptide, eGFR: estimated glomerular filtration rate
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protein 27. Activation of these pathways leads to en-
hanced synthesis of DNA, upregulation of TGF-β1, PAI-
1, collagen-1, fibronectin and cyclooxygenase-2, inde-
pendent of the classic renin-angiotensin-aldosterone sys-
tem [8, 9]. This suggests that stimulation of (pro)reninFig. 2 Plasma prorenin concentrations and renin activity in coronary artery
are shown in box plots. A line in each box indicates the median. The upperreceptors may exert important effects on the cardiovas-
cular system. (Pro)renin receptors have been localized in
various tissues such as the brain, kidneys, heart and vas-
cular smooth muscle cells [10]. Stimulation of (pro)re-
nin receptors has been reported to cause diabetic
nephropathy, [3] cardiac injury [4] and vascular damagedisease and non- coronary artery disease groups. Non-parametric data
and lower limits of each box are the 1st and 3rd quartiles, respectively
Table 3 Accuracy of plasma prorenin and PRA for detecting coronary artery disease
Cutoff Sensitivity Specificity PPV NPV
Prorenin (pg/ml) 1,100 25 (15–34) 96 (92–100) 94 (88–99) 36 (25–46)
PRA (ng/ml/hr) 0.8 36 (26–46) 69 (59–79) 72 (63–81) 32 (22–42)
The optimal cutoff values were determined by receiver-operating-characteristic curve analysis. Data are percentages. Numbers in parentheses are 95 % confidence
intervals. PPV: positive predictive value, NPV: negative predictive value. PRA: plasma renin activity
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edly increased in patients with diabetes mellitus with end-
organ damage [7, 11]. This suggests that increased plasma
prorenin that stimulated (pro)renin receptors resulted in
kidney damage.
We measured plasma prorenin concentration in patients
with CAD and found that there were patients with CAD
that had low plasma prorenin concentration, although pa-
tients with high plasma prorenin concentration frequently
had CAD. This suggested that there may be two types of
coronary stenosis: one type that is sensitive to prorenin and
another type that is not. Increased plasma prorenin may
have affected coronary artery stenosis through activation of
(pro)renin receptors in vascular smooth muscle cells, since
activation of (pro)renin receptors has been reported to
cause vascular damage [5].
In the present study, patients with a high plasma pro-
renin concentration (>1,100 pg/ml) frequently suffered
CAD (94 %), and accuracy of an elevated plasma prorenin
concentration to detect CAD was greater than that of an









Fig. 3 Receiver operating characteristic curves (ROC) analysis. AUC: area unstrated that high PRA was an independent predictor of
major vascular events and mortality in a stable population
of high-risk patients with atherosclerosis and/or diabetes
[12]. The results of the present study suggested that the
plasma prorenin concentration may also be a marker
of CAD and/or atherosclerosis. Although, there were
patients with CAD that had a low plasma prorenin
concentration, patients with a high plasma prorenin
concentration frequently had CAD. This may be because a
high plasma prorenin concentration induces coronary sten-
osis by a mechanism that does not involve endothelial in-
jury or lipid accumulation in plaque. A previous study
showed that prorenin induced the growth of extracellar
matrix components rather than endothelial damage [13].
Another study reported that prorenin enhanced human
vascular smooth muscle cell proliferation due to activation
of extracellular-signal-related protein kinase in a dose- and
time-dependent manner [14]. Therefore, prorenin may in-
duce stenosis from a medial site due to vascular smooth
muscle cell proliferation. The detailed mechanisms by










Table 4 Laboratory and clinical characteristics in the CAD group with patients stratified based on prorenin levels
Prorenin≥ 1,100 Prorenin < 1,100 p-value
(n = 15) (n = 44)
Age, years 72 ± 6 67 ± 9 0.047
Body mass index 24.4 ± 3.3 23.7 ± 2.9 0.43
Prorenin (ng/ml) 1521 (1261–1937) 435 (227–601) <0.001
Plasma renin concentration (pg/ml) 12.1 (6.9 - 17.5) 5.6 (4.1 - 8.5) 0.001
Plasma renin activity (ng/ml/hr) 2.3 (1.1 - 4.2) 0.8 (0.6 - 1.6) 0.017
Aldosterone (pg/ml) 82 (69–92) 69 (58–104) 0.63
Brain natriuretic peptide (ng/ml) 43 (24–76) 25 (12–60) 0.23
Cystatin C (mg/dl) 1.19 ± 0.54 1.05 ± 0.29 0.21
Creatinine (mg/ml) 0.91 ± 0.34 0.83 ± 0.24 0.32
Estimated GFR (ml/min/1.73 m2) 65.8 ± 21.8 70.9 ± 18.3 0.38
Blood urea nitrogen (mg/dl) 17.2 ± 4.5 15.4 ± 3.9 0.16
Hemoglobin A1c (%) 6.2 ± 0.7 6.0 ± 1.2 0.67
Total cholesterol (mg/dl) 178 ± 33 191 ± 33 0.19
LDL cholesterol (mg/dl) 101 ± 29 115 ± 31 0.14
HDL cholesterol (mg/dl) 49 ± 12 48 ± 14 0.74
Triglycerides (mg/dl) 141 ± 60 138 ± 77 0.91
C-reactive protein (mg/dl) 0.13 ± 0.17 0.20 ± 0.22 0.32
Total protein (g/dl) 6.80 ± 0.24 6.70 ± 0.42 0.43
Albumin (g/dl) 4.15 ± 0.24 4.12 ± 0.32 0.74
Sodium (mEq/l) 139.6 ± 2.8 140.6 ± 2.1 0.13
Potassium (mEq/l) 4.27 ± 0.37 3.97 ± 0.32 0.005
Cl (mEq/l) 104.9 ± 3.8 105.5 ± 2.7 0.42
Numerical data are expressed as the mean ± one standard deviation. Non-parametric data are expressed as the median (interquartile range). GFR: glomerular
filtration rate
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into the relationship between plasma prorenin and CAD.Plasma prorenin concentration and other diseases
Plasma prorenin concentration is determined by the bal-
ance between clearance of prorenin from the circulation
and production of prorenin. We assessed the relation-
ship between plasma prorenin concentration and eGFR,
and there was no correlation between them. This sug-
gests that clearance of prorenin from the kidney is not
decreased and a higher plasma prorenin concentration is
not due to decreased clearance of prorenin from the cir-
culation. The plasma prorenin concentration was not
correlated with LVEF or plasma BNP levels, suggesting
that plasma prorenin concentration is not affected by
cardiac function.
In the present study, there was also no significant differ-
ence in the plasma prorenin concentration between pa-
tients with and without DM. However, the plasma prorenin
concentration has been reported to be increased in patients
who have DM with complications [6]. This discrepancymay be because the present study included DM patients
both with and without complications.
Study limitations
There are several limitations of the present study. First,
the relationship between renin and cardiovascular dis-
ease may be obscured by the use of various drugs such
as ACEIs, ARBs, beta-blockers and diuretics because
these drugs modify PRA. In addition, the role of plasma
prorenin in patients with CAD is still unclear. Second, a
relatively small number of the patients were enrolled in
the present study. Thus, the study may have been under-
powered to definitively determine the relationship be-
tween the incidence of CAD and plasma prorenin
concentration. A study in a larger population is needed
to elucidate the relationship between the plasma prore-
nin concentration and the progression of CAD.
Conclusions
Although, there were patients with CAD that had a
low plasma prorenin concentration (≤1,100 pg/ml),
patients with a high plasma prorenin concentration
Yoshida et al. Biomarker Research  (2015) 3:18 Page 7 of 7(>1,100 pg/ml) frequently had CAD. This may be because
a high plasma prorenin concentration (>1,100 pg/ml)
induces coronary stenosis by a mechanism that does
not involve endothelial injury or lipid accumulation in
plaque. The present study is a first report that demon-
strated the relationship between plasma prorenin con-
centration and CAD.
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